Bioorthogonal liposome-based sequential drug delivery system for enhanced tumor accumulation and targeted therapy

Area of Science:

• Biomedical Engineering
• Drug Delivery Systems
• Cancer Therapy

Background:

• Effective drug accumulation at tumor sites is a major challenge in cancer therapy.
• Poor targeting and off-target effects limit the efficacy of conventional treatments.
• Novel drug delivery systems are needed to improve tumor specificity and therapeutic outcomes.

Purpose of the Study:

• To develop and evaluate a novel liposome-based drug delivery system utilizing bioorthogonal chemistry.
• To enhance tumor-specific drug accumulation and achieve controlled drug release.
• To improve therapeutic outcomes in cancer treatment by minimizing off-target effects.

Main Methods:

• Engineered DBCO- and azide-modified liposomes for optimized encapsulation, stability, and drug release.
• Conducted in vitro cellular assays to assess uptake and toxicity.
• Performed in vivo biodistribution and efficacy studies in tumor-bearing models.

Main Results:

• Bioorthogonal liposomes showed significantly enhanced tumor accumulation compared to free doxorubicin and conventional liposomes.
• Achieved a 60% tumor inhibition rate with improved cellular uptake and retention in vitro.
• Demonstrated superior therapeutic efficacy in vivo, with increased tumor apoptosis, suppressed proliferation, and reduced systemic toxicity.

Conclusions:

• Bioorthogonal liposomes represent a promising platform for precise drug delivery in cancer therapy.
• This approach offers enhanced tumor targeting, improved efficacy, and reduced systemic toxicity.
• Findings support the clinical translation potential for next-generation targeted cancer therapies.